232 related articles for article (PubMed ID: 17188962)
1. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
Lynch PM
Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
[No Abstract] [Full Text] [Related]
2. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
3. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
4. Clinical inquiries. Do COX-2 inhibitors worsen renal function?
Wall R; Strickland C; Jamieson B; Lo V
J Fam Pract; 2007 Nov; 56(11):957-8. PubMed ID: 17976347
[No Abstract] [Full Text] [Related]
5. VICTOR spoiled?
Goldberg RM; Bertagnolli MM
J Clin Oncol; 2010 Oct; 28(30):4546-8. PubMed ID: 20837951
[No Abstract] [Full Text] [Related]
6. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
[TBL] [Abstract][Full Text] [Related]
7. Risks and benefits of celecoxib to prevent recurrent adenomas.
Psaty BM; Potter JD
N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
[No Abstract] [Full Text] [Related]
8. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
10. Rofecoxib in mild cognitive impairment.
Ownby RL
Curr Psychiatry Rep; 2006 Feb; 8(1):9-10. PubMed ID: 16513035
[No Abstract] [Full Text] [Related]
11. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
12. COX-2 inhibitors: cancer prevention or cardiovascular risk?
Senior K
Lancet Oncol; 2005 Feb; 6(2):68. PubMed ID: 15704289
[No Abstract] [Full Text] [Related]
13. The COX-2 story: is any drug completely "safe?".
DuBois RN
Gastroenterology; 2006 Jan; 130(1):6. PubMed ID: 16401461
[No Abstract] [Full Text] [Related]
14. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
Cen YY
Circulation; 2007 Mar; 115(12):e348; author reply e349. PubMed ID: 17389275
[No Abstract] [Full Text] [Related]
15. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
[No Abstract] [Full Text] [Related]
16. The withdrawal of rofecoxib.
Arellano FM
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
[No Abstract] [Full Text] [Related]
17. COX-2 inhibitors and heart.
Manoria P; Manoria PC
Indian Heart J; 2005; 57(6):772-7. PubMed ID: 16521658
[No Abstract] [Full Text] [Related]
18. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
Lévesque LE; Brophy JM; Zhang B
CMAJ; 2006 May; 174(11):1563-9. PubMed ID: 16670396
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]